Novasep and instrAction have allied to develop large scale chromatography processes for purifying synthetic and semi-synthetic compounds.
Combining the firms’ capabilities will create a more economic and effective purification service for complex pharma compounds. Furthermore, by working closely, providing clients a single point of contact and streamlining project management the firms expect to cut process development times.
To realise these benefits the companies have entered into a strategic alliance which builds upon earlier collaborations. The venture will use the active pharmaceutical ingredient- (API) selective stationary phases from instrAction and the production and chromatography capacity at Novasep.
Clients outsourcing to the alliance can have the most appropriate API-selective stationary phase identified from the library of more than 3,000 phases operated by instrAction. Process performance optimisation can then be performed by Novasep using its simulation software.
Purification and synthesis can then be performed by Novasep. Alternatively, the process can be transferred to the client. This includes the supply of a turnkey chromatography process guaranteed by Novasep and the API-selective stationary phase by instrAction.
By taking this combined approach Novasep and instrAction will provide a purification process or service with guaranteed, optimised and cost-effective performance. Clients will secure key process intellectual property for their molecules, such as new molecular entities or generic APIs.
René De Vaumas, executive vice president, synthesis business development at Novasep, said the increasing complexity of compounds has made processes such as crystallisation and normal or reversed phase chromatography too expensive.
“instrAction’s API-selective stationary phases have already demonstrated dramatically improved purification costs for several difficult-to-purify compounds at medium to large scale”, said De Vaumas.
Thomas Schwarz, CEO of instrAction, said: “We believe that, together, instrAction and Novasep will develop solutions that will provide great improvement in the purification of a number of pharmaceutical compounds.”